Published in Cancer Biol Ther on December 22, 2003
Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol (2007) 3.47
MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem (2011) 1.88
Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J (2005) 1.85
Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem (2011) 1.46
Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol (2008) 1.44
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem (2009) 1.30
Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest (2008) 1.27
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle (2011) 1.07
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol (2015) 1.01
p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab (2005) 1.01
Molecular interplay between leptin, insulin-like growth factor-1, and β-amyloid in organotypic slices from rabbit hippocampus. Mol Neurodegener (2011) 0.96
Skp2 is a promising therapeutic target in breast cancer. Front Oncol (2012) 0.95
Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther (2006) 0.95
Adrenocortical tumors and hyperplasias in childhood--etiology, genetics, clinical presentation and therapy. Pediatr Endocrinol Rev (2006) 0.92
An intermediate-conductance Ca(2+)-activated K (+) channel mediates B lymphoma cell cycle progression induced by serum. Pflugers Arch (2007) 0.91
Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling. Cancer Res (2010) 0.90
Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer. J Cancer Res Clin Oncol (2012) 0.90
Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br J Cancer (2013) 0.88
Expression of the insulin-like growth factor and insulin systems in the luteinizing macaque ovarian follicle. Fertil Steril (2009) 0.86
A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Res (2016) 0.86
Somatostatin and cancer: applying endocrinology to oncology. Cancer Biol Ther (2004) 0.84
Influence of Intramuscular Application of Autologous Conditioned Plasma on Systemic Circulating IGF-1. J Sports Sci Med (2011) 0.83
Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line. PLoS One (2012) 0.82
Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system. Cancer Lett (2007) 0.81
IGFBP3 mRNA expression in benign and malignant breast tumors. Breast Cancer Res (2007) 0.81
Posttranscriptional regulation of insulin family ligands and receptors. Int J Mol Sci (2013) 0.79
Pediatric brain tumor treatment: growth consequences and their management. Pediatr Endocrinol Rev (2010) 0.79
IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review). Oncol Rep (2014) 0.78
POTENTIAL NON-GROWTH USES OF rhIGF-I. Growth Genet Horm (2007) 0.78
Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Transl Androl Urol (2013) 0.78
Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A. Growth Horm IGF Res (2007) 0.77
Cancer. Adv Exp Med Biol (2005) 0.77
Correlation between insulin‑like growth factor binding protein 3 and metastasis‑associated gene 1 protein in esophageal squamous cell carcinoma. Mol Med Rep (2016) 0.75
Doxorubicin Induces Inflammatory Modulation and Metabolic Dysregulation in Diabetic Skeletal Muscle. Front Physiol (2016) 0.75
IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process. Oncotarget (2016) 0.75
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget (2016) 0.75
Older age at the completion of linear growth is associated with an increased risk of adult glioma. Cancer Causes Control (2017) 0.75
The inhibitory effects of NKX3.1 on IGF-1R expression and its signalling pathway in human prostatic carcinoma PC3 cells. Asian J Androl (2011) 0.75
Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci (2017) 0.75
Cellular survival: a play in three Akts. Genes Dev (1999) 17.05
Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J (1986) 6.62
Regulation of cadherin adhesive activity. J Cell Biol (2000) 5.63
Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A (1999) 4.84
Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature (1995) 3.55
The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev (1999) 3.54
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A (1993) 2.58
Cycling to cancer with cyclin D1. Cancer Biol Ther (2002) 2.58
Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol (2000) 2.47
Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.38
Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res (1997) 2.34
The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem (2003) 2.29
Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol (1996) 2.15
Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A (1996) 2.09
The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology (2002) 2.03
Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res (2002) 1.96
Insulin-like growth factor physiology and cancer risk. Eur J Cancer (2000) 1.71
Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev (2002) 1.68
Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem (2000) 1.67
Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res (1999) 1.63
A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res (2003) 1.61
Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem (1997) 1.58
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev (2003) 1.56
Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab (1992) 1.53
Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem (2000) 1.51
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res (2001) 1.46
Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A (2000) 1.45
Regulatory mechanisms at the mouse Igf2/H19 locus. Mol Cell Biol (2001) 1.41
Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J (1993) 1.37
Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res (2000) 1.37
Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene (2003) 1.32
Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci U S A (1997) 1.25
The IGF system in thyroid cancer: new concepts. Mol Pathol (2001) 1.21
Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther (2003) 1.20
Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab (1998) 1.18
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer (2000) 1.15
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab (2003) 1.15
Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem (1993) 1.13
Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther (2002) 1.09
Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis. Cancer Res (1996) 1.07
P53 and IGFBP-3: apoptosis and cancer protection. Mol Genet Metab (2000) 1.06
Minireview: Integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinology (2003) 1.06
PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene (2002) 1.05
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res (2001) 1.03
Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res (2003) 1.03
Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol (1995) 1.00
Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology (2002) 0.99
Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer (2001) 0.99
Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg (2001) 0.98
Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem (2000) 0.97
Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Mol Morphol (2000) 0.93
Functional role of alpha-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci (2002) 0.91
Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology (2001) 0.91
Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression. Cancer Res (1998) 0.90
IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol (2002) 0.89
Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit. J Biol Chem (2001) 0.88
Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res Treat (2001) 0.88
Diet and cancer prevention studies in p53-deficient mice. J Nutr (2001) 0.87
Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem (2001) 0.87
Growth hormone and prostate cancer: guilty by association? J Endocrinol Invest (1999) 0.87
PTEN/MMAC1 overexpression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells. Cell Growth Differ (2001) 0.86
Insulin like growth factor-1 selectively regulates the expression of matrix metalloproteinase-2 in malignant H-ras transformed cells. Mol Cell Biochem (2001) 0.85
Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells. Exp Cell Res (2002) 0.85
Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells. FEBS Lett (2002) 0.84
Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumour Biol (2002) 0.82
Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinology (2001) 0.82
Transcriptional activation of cathepsin D gene expression by growth factors. J Mol Endocrinol (2000) 0.81
IGF status is altered by tamoxifen in patients with breast cancer. Mol Pathol (2001) 0.80
Alterations in tumorigenicity of embryonal carcinoma cells by IGF-I triple-helix induced changes in immunogenicity and apoptosis. Life Sci (2000) 0.79
Functional interactions between colony-stimulating factors and the insulin family hormones for human myeloid leukemic cells. Cancer Res (1990) 0.77
Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. Br J Cancer (2001) 0.77